Ordering
Available Variants50 mg
CHA.44758-50mg
Price
€148.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.44758-50mg | €148.00 |
≥95%
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C17H18N4O4 · xHCl |
|---|---|
| CAS Number | 2228029-82-9 |
| Molecular Weight | 342.35 (free base basis) |
| UNSPSC Code | 12352101 |
| NACRES | NA.21 |
| MDL number | MFCD34183126 |
Safety Information Handling visibility
| pictograms |
GHS08
 GHS08
|
|---|---|
| signalword | Danger |
| hcodes | H360D |
| pcodes | P201 - P202 - P280 - P308 + P313 - P405 - P501 |
| Hazard Classifications | Repr. 1B |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
C5-Pomalidomide-piperazine hydrochloride, with a CAS number of 2228029-82-9, is a synthetic compound that has garnered significant attention in the realm of pharmaceutical research. This chemical entity is a derivative of pomalidomide, a known immunomodulatory drug, and has been designed to exhibit enhanced potency and selectivity. The incorporation of a piperazine moiety into the pomalidomide scaffold is intended to modulate its biological activity, potentially leading to improved therapeutic outcomes. As a result, C5-Pomalidomide-piperazine hydrochloride is being investigated for its potential applications in the treatment of various diseases, including hematological malignancies and inflammatory disorders. Further research is necessary to fully elucidate the pharmacological properties and clinical potential of this compound, which may ultimately contribute to the development of novel therapeutic strategies.
